Jonathan Lu

1.1k citations

23 papers · 957 indexed · h-index 17

Impact in

Biochemistry top 5%
- Antioxidant Activity and Oxidative Stress
Immunology top 5%
- Atherosclerosis and Cardiovascular Diseases
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms

Papers in ⓘ

Biochemistry 4
- Antioxidant Activity and Oxidative Stress 4
Immunology 12
- Atherosclerosis and Cardiovascular Diseases 10
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms 3

Co-authors: Chu‐Huang Chen (18 shared papers)Tatsuya Sawamura (8 shared papers)Liang‐Yin Ke (6 shared papers)Chih‐Sheng Chu (5 shared papers)Philip D. Henry (2 shared papers)Chao-Yuh Yang (3 shared papers)Daming Tang (3 shared papers)Jeffrey P. Walterscheid (3 shared papers)
Journals: Circulation (2 papers)PLoS ONE (2 papers)Journal of Clinical Medicine (1 paper)International Journal of Pharmaceutics (1 paper)Circulation Research (1 paper)
Partner nations: United States Taiwan Japan

In The Last Decade

Jonathan Lu

23 papers receiving 942 citations

Peers

Countries citing papers authored by Jonathan Lu

Since Specialization

Citations

This map shows the geographic impact of Jonathan Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan Lu more than expected).

Fields of papers citing papers by Jonathan Lu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan Lu. The network helps show where Jonathan Lu may publish in the future.

Co-authors

The 25 scholars most cited alongside Jonathan Lu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jonathan Lu Line = papers co-authored together Jonathan Lu links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 23 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Low-Density Lipoprotein in Hypercholesterolemic Human Plasma Induces Vascular Endothelial Cell Apoptosis by Inhibiting Fibroblast Growth Factor 2 Transcription Circulation ·Chu‐Huang Chen, Tao Jiang, Jun-Hai Yang, Wei Jiang, Jonathan Lu, Gopal K. Marathe, Henry J. Pownall, Christie M. Ballantyne, Thomas M. McIntyre, Philip D. Henry, Chao-Yuh Yang	2003	134
2	Mediation of Electronegative Low-Density Lipoprotein Signaling by LOX-1 Circulation Research ·Jonathan Lu, Junhai Yang, Alan R. Burns, Hsin‐Hung Chen, Daming Tang, Jeffrey P. Walterscheid, Shinichi Suzuki, Chao-Yuh Yang, Tatsuya Sawamura, Chu‐Huang Chen	2009	113
3	Interplay between CRP, Atherogenic LDL, and LOX-1 and Its Potential Role in the Pathogenesis of Atherosclerosis Clinical Chemistry ·Nicole Stancel, Chih-Chieh Chen, Liang‐Yin Ke, Chih‐Sheng Chu, Jonathan Lu, Tatsuya Sawamura, Chu‐Huang Chen	2015	107
4	Electronegative LDL circulating in smokers impairs endothelial progenitor cell differentiation by inhibiting Akt phosphorylation via LOX-1 Journal of Lipid Research ·Daming Tang, Jonathan Lu, Jeffrey P. Walterscheid, Hsin‐Hung Chen, David Engler, Tatsuya Sawamura, Po‐Yuan Chang, Hazim J. Safi, Chao-Yuh Yang, Chu‐Huang Chen	2007	68
5	Highly electronegative LDL from patients with ST-elevation myocardial infarction triggers platelet activation and aggregation Blood ·Hua‐Chen Chan, Liang‐Yin Ke, Chih‐Sheng Chu, An‐Sheng Lee, Ming‐Yi Shen, Miguel A. Crúz, Jing‐Fang Hsu, Kai‐Hung Cheng, Hsiu‐Chuan Chan, Jonathan Lu, Wen‐Ter Lai, Tatsuya Sawamura, Sheng‐Hsiung Sheu, Jeng‐Hsien Yen, Chu‐Huang Chen	2013	68
6	Electronegative LDL Impairs Vascular Endothelial Cell Integrity in Diabetes by Disrupting Fibroblast Growth Factor 2 (FGF2) Autoregulation Diabetes ·Jonathan Lu, Wei Jiang, Jun-Hai Yang, Po‐Yuan Chang, Jeffrey P. Walterscheid, Hsin‐Hung Chen, Marco Marcelli, Daming Tang, Yuan-Teh Lee, Warren S.‐L. Liao, Chao-Yuh Yang, Chu‐Huang Chen	2007	62
7	Fibroblast Growth Factor 2: From Laboratory Evidence to Clinical Application Current Vascular Pharmacology ·Chu‐Huang Chen, Simon M. Poucher, Jonathan Lu, Philip D. Henry	2004	57
8	Aspirin protects human coronary artery endothelial cells against atherogenic electronegative LDL via an epigenetic mechanism: a novel cytoprotective role of aspirin in acute myocardial infarction Cardiovascular Research ·Po‐Yuan Chang, Yi-Jie Chen, Fu‐Hsiung Chang, Jonathan Lu, Wen-Huei Huang, Tzu-Ching Yang, Yuan-Teh Lee, Shwu‐Fen Chang, Shao‐Chun Lu, Chu‐Huang Chen	2013	49
9	Human electronegative LDL induces mitochondrial dysfunction and premature senescence of vascular cells in vivo Aging Cell ·Yu‐Chen Wang, An‐Sheng Lee, Long‐Sheng Lu, Liang‐Yin Ke, Wei‐Yu Chen, Jian‐Wen Dong, Jonathan Lu, Zhenping Chen, Chih‐Sheng Chu, Hua‐Chen Chan, Taha Yusuf Kuzan, Ming‐Hsien Tsai, Wen‐Li Hsu, Richard A. F. Dixon, Tatsuya Sawamura, Kuan‐Cheng Chang, Chu‐Huang Chen	2018	47
10	Electronegative Low-Density Lipoprotein Increases C-Reactive Protein Expression in Vascular Endothelial Cells through the LOX-1 Receptor PLoS ONE ·Chih‐Sheng Chu, Yu-Chen Wang, Long‐Sheng Lu, Brian Walton, H. Ramazan Yılmaz, Roger Huang, Tatsuya Sawamura, Richard A. F. Dixon, Wen-Ter Lai, Chu‐Huang Chen, Jonathan Lu	2013	41
11	Chemical composition-oriented receptor selectivity of L5, a naturally occurring atherogenic low-density lipoprotein Pure and Applied Chemistry ·Liang‐Yin Ke, David Engler, Jonathan Lu, Risë K. Matsunami, Hua‐Chen Chan, Guei‐Jane Wang, Chao-Yuh Yang, Jan‐Gowth Chang, Chu‐Huang Chen	2011	33
12	Effects of Electronegative VLDL on Endothelium Damage in Metabolic Syndrome Diabetes Care ·Chu‐Huang Chen, Jonathan Lu, Shuhua Chen, Roger Huang, H. Ramazan Yılmaz, Jian‐Wen Dong, MacArthur Elayda, Richard A. F. Dixon, Chao-Yuh Yang	2012	31
13	Low-Density Lipoprotein Electronegativity Is a Novel Cardiometabolic Risk Factor PLoS ONE ·Jing‐Fang Hsu, Tzu‐Chieh Chou, Jonathan Lu, Shuhua Chen, Fang-Yu Chen, Ching‐Chu Chen, Jeffrey Chen, MacArthur Elayda, Christie M. Ballantyne, Steven Shayani, Chu‐Huang Chen	2014	24
14	The role of electronegative low-density lipoprotein in cardiovascular diseases and its therapeutic implications Trends in Cardiovascular Medicine ·Sümeyya Akyol, Jonathan Lu, Ömer Akyol, Fatih Akçay, Ferah Armutçu, Liang‐Yin Ke, Chu‐Huang Chen	2016	24
15	Enhanced Sphingomyelinase Activity Contributes to the Apoptotic Capacity of Electronegative Low-Density Lipoprotein Journal of Medicinal Chemistry ·Liang‐Yin Ke, Hua‐Chen Chan, Chih-Chieh Chen, Jonathan Lu, Gopal K. Marathe, Chih‐Sheng Chu, Hsiu-Chuan Chan, Chung-Ya Wang, Yi‐Ching Tung, Thomas M. McIntyre, Jeng‐Hsien Yen, Chu‐Huang Chen	2016	20
16	Detection of a High Ratio of Soluble to Membrane‐Bound LOX‐1 in Aspirated Coronary Thrombi From Patients With ST‐Segment–Elevation Myocardial Infarction Journal of the American Heart Association ·An‐Sheng Lee, Yu‐Chen Wang, Shih‐Sheng Chang, Ping‐Hang Lo, Chia‐Ming Chang, Jonathan Lu, Alan R. Burns, Chu‐Huang Chen, Akemi Kakino, Tatsuya Sawamura, Kuan‐Cheng Chang	2020	18
17	Perturbations in Endothelial Dysfunction-Associated Pathways in the Nitrofen-Induced Congenital Diaphragmatic Hernia Model Journal of Vascular Research ·Siqin Zhaorigetu, Henry Bair, Jonathan Lu, Di Jin, Scott D. Olson, Matthew T. Harting	2017	16
18	Incidence and characteristics of inappropriate and false-positive cardiac catheterization laboratory activations in a regional primary percutaneous coronary intervention program American Heart Journal ·Jonathan Lu, Akshay Bagai, Chris Buller, Asim N. Cheema, John Graham, Michael J.B. Kutryk, Jo-Ann Christie, Neil Fam	2015	15
19	Combined LDL and VLDL Electronegativity Correlates with Coronary Heart Disease Risk in Asymptomatic Individuals Journal of Clinical Medicine ·Ming‐Yi Shen, Jing‐Fang Hsu, Fang-Yu Chen, Jonathan Lu, Chia‐Ming Chang, Mohammad Madjid, Juliette Dean, Richard A. F. Dixon, Steven Shayani, Tzu‐Chieh Chou, Chu‐Huang Chen	2019	14
20	Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function European Journal of Clinical Pharmacology ·Renli Teng, Sharen Muldowney, Yonggang Zhao, Jolene Kay Berg, Jonathan Lu, Naeem D. Khan	2018	6

About Jonathan Lu

Jonathan Lu is a scholar working on Biochemistry, Immunology, Cardiology and Cardiovascular Medicine, Internal Medicine and Epidemiology, having authored 23 papers that have together received 957 indexed citations. Recurring topics across this work include Atherosclerosis and Cardiovascular Diseases (10 papers), Adipokines, Inflammation, and Metabolic Diseases (6 papers), Lipoproteins and Cardiovascular Health (5 papers), Antioxidant Activity and Oxidative Stress (4 papers), Neutrophil, Myeloperoxidase and Oxidative Mechanisms (3 papers), Antiplatelet Therapy and Cardiovascular Diseases (3 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (2 papers) and Kruppel-like factors research (2 papers). The work is most often cited by research in Biochemistry (156 citations), Immunology (479 citations), Cardiology and Cardiovascular Medicine (192 citations), Endocrinology, Diabetes and Metabolism (132 citations) and Surgery (342 citations). Jonathan Lu has collaborated with scholars based in United States, Taiwan and Japan. Frequent co-authors include Chu‐Huang Chen, Tatsuya Sawamura, Liang‐Yin Ke, Chih‐Sheng Chu, Philip D. Henry, Chao-Yuh Yang, Daming Tang, Jeffrey P. Walterscheid, Chao-Yuh Yang and Po‐Yuan Chang. Their work appears in journals such as Circulation, PLoS ONE, Journal of Clinical Medicine, International Journal of Pharmaceutics and Circulation Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact